Industry News
Biotechnology Industry News
Tubulis’ next-generation ADC has…
Tubulis’ next-generation ADC has been tied to an overall response rate of 59% as the German biotech tastes its first clinical success.
GSK may be happy with the latest…
GSK may be happy with the latest readouts from two Hansoh-partnered ADCs, but the Big Pharma’s oncology R&D chief told Fierce to “stay tuned” for the company’s own data.
Cancer biotech Vivace Therapeutics…
Cancer biotech Vivace Therapeutics is tuning up for a phase 3 trial after its potential first-in-class small molecule scored a 32% objective response rate in patients with treatment-resistant mesothelioma.
Xoma Royalty and Lava Therapeutics…
Xoma Royalty and Lava Therapeutics are turning the temperature down, dropping both the cash per share offer and closing cash conditions for an acquisition inked back in August.
For the second year running,…
For the second year running, Pfizer has arrived at the European Society for Medical Oncology (ESMO) conference armed with data showing its one-time heart failure hopeful ponsegromab can treat a wasting syndrome.
Danish vaccine developer Evaxion…
Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring a 75% objective response rate (ORR) in patients with advanced melanoma after two years. But the trial
Roche’s giredestrant was shown…
Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% in a specific cohort of a phase 3 trial.
For the second time, Astellas is…
For the second time, Astellas is walking away from Taysha Gene Therapies, this time choosing not to license the biotech’s adeno-associated-virus-based therapy designed to treat a rare neurodevelopmental condition.
Less than two years after laying…
Less than two years after laying out plans to divest its China operations and become a U.S.-focused biotech, I-Mab Biopharma is re-staking its claim in the Asia-Pacific region.
Hansoh has announced a deal with…
Hansoh has announced a deal with Roche worth up to $1.45 billion biobucks to grant the Swiss drugmaker a global license to develop, manufacture and sell its experimental ADC. At the same time, Rani has
The FDA made waves in early…
The FDA made waves in early September when it announced a plan to publicly release complete response letters, or CRLs, at the same time they are issued to sponsoring companies. What risks and opportunities does
Bristol Myers Squibb touted a 55%…
Bristol Myers Squibb touted a 55% overall response rate from one cohort of an early-stage study of its EGFRxHER3 antibody-drug conjugate.
The FDA’s cancellation of a…
The FDA’s cancellation of a meeting to discuss the next steps in a R&D program has prompted Kezar Life Sciences to prepare to lay off staff and explore strategic alternatives.
The FDA has handed out the first…
The FDA has handed out the first nine national priority vouchers, positioning companies including Merck KGaA, Regeneron and Sanofi to complete the approval process in one to two months.
Gilead’s Kite Pharma is doubling…
Gilead’s Kite Pharma is doubling down on in vivo CAR-T, this time inking a deal worth up to $1.64 billion biobucks with China biotech Pregene Biopharma.
The trials demonstrated the…
The trials demonstrated the benefits of Praxis' ulixacaltamide in essential tremor after a previously grim outlook at an interim analysis of one of the studies earlier this year.
French antibody specialist…
French antibody specialist Adcytherix has added a €105 million ($122 million) series A to its coffers, which the Marseille-based biotech will use to push its lead antibody-drug conjugate into clinical trials.
Dianthus Therapeutics is offering…
Dianthus Therapeutics is offering Nanjing Leads Biolabs up to $1 billion biobucks for licensing rights to a bifunctional fusion protein designed to treat certain autoimmune disorders.
University of Michigan spinout…
University of Michigan spinout Evoq Therapeutics has struck its third major partnership with a biopharma powerhouse, signing on with Sanofi in a deal worth up to $500 million. The agreement comes after Evoq entered deals
AstraZeneca has returned to its…
AstraZeneca has returned to its longtime AI partner Immunai with a new deal worth up to $85 million to advance a target for a new inflammatory bowel disease therapy.